Is it possible to monitor children's cognitive performance in their daily lives without requiring them to visit a research center for each measurement? In Singapore, SYRES Asia coordinated a home-based protocol for Activ'Inside, combining digital tests, parental observations, and medical supervision. Among the 41 children analyzed, the overall cognitive score improved by 17,1% after 28 days of taking a dietary supplement containing grape and blueberry extracts.
Measuring both performance and everyday life
Activ'Inside aimed to explore the evolution of cognitive functions in children taking 150 mg of Memophenol™ daily , a grape and blueberry extract rich in polyphenols. The protocol's objective was to monitor several complementary dimensions: the children's responses to cognitive exercises, and then the behaviors their parents observed in everyday life.
SYRES Asia recruited families from its Singaporean panel, organized home follow-up, and coordinated medically supervised assessments. The study took place from July 6 to August 2, 2025, with healthy children aged 7 to 12 years. Fifty-two children were included, and 41 completed the study according to the protocol (21 girls and 20 boys, with an average age of 9,5 years). The remaining eleven were excluded from the analysis due to non-compliance with the guidelines.
The protocol in brief
Element | Device |
|---|---|
Product use | One stick containing 150 mg of Memophenol™, diluted in water and taken every morning at breakfast for 28 days |
Children's tests | Six CogniFit Kids mini-games to be played at home, under parental supervision, in sessions of approximately 15 to 20 minutes. |
Measurement moments | Before the first dose (Day 0), two hours after it, then on Day 14 and Day 28 |
Parents' observations | BRIEF-2 questionnaire on days 0, 14 and 28; satisfaction questionnaire on day 28 |
Tolerance | Collection of any adverse events under medical supervision |
CogniFit Kids provided an overall score and scores specifically for memory, attention, reasoning, perception, and coordination. The BRIEF-2 allowed parents to assess their child's executive functions, such as the regulation of behavior and emotions. On this second scale, a lower score indicates that parents report fewer difficulties.
Cognitive scores rising over time.
Compared to the test performed before the first dose, the overall CogniFit cognitive score improved at each of the three measurement points:
+9,5% two hours after the first dose;
+13,9% at J14;
+17,1% at J28.
These three differences are statistically significant in the published analysis ( p < 0,001). By day 28, several areas had also changed:
Perception: +29,8% ;
Memory: +22,9% ;
Reasoning: +14,5% ;
Warning: +9,1% ;
Coordination: +6,3%.
These are results obtained from numerical exercises. These percentages do not describe an increase in IQ or a measurable improvement in academic grades.
What the parents noticed
Responses to the BRIEF-2 followed the same general trend. The overall composite score decreased by 8,3% at day 14 and then by 12,9% at day 28 compared to baseline ( p < 0,001). After 28 days, all three indices had also decreased.
Behavioral regulation: −11,5% ;
Emotional regulation: −14,4% ;
Cognitive regulation: −12,8%.
The final questionnaire provides another perspective, that of the families:
63% of parents noticed an improvement in their child's attention span;
66% judged the product to be generally effective;
61% indicated they wanted to continue using it or buying it.
These responses shed light on the experience of families, but remain opinions expressed by parents who were familiar with the product their child was taking.
Regular intake and few reported incidents
Over the 28 days, 80,5% of the children analyzed did not miss any doses; the others missed one or two. A mild and transient digestive event was reported on the first day. It resolved spontaneously, without discontinuing the product. The publication reports a tolerability rate of 97,6% in this sample . However, the duration and size of the study do not allow for conclusions to be drawn regarding the safety of the product for all children or for prolonged use.
Promising observations, to be confirmed
This protocol demonstrates the value of combining child-administered tests, parental observations, and medication intake monitoring in a home-based study. These approaches describe different facets of the experience over four weeks, with repeated measurements rather than a single final assessment.
The scope of the results remains exploratory . The study was open-label, without a placebo or control group. The children may have progressed simply because they became familiar with the mini-games; parental expectations may have influenced their responses. Therefore, it is not possible to definitively attribute the observed improvements to Memophenol™ . A randomized, double-blind, placebo-controlled pediatric trial would be necessary to confirm an effect of the product and measure its magnitude.
For SYRES, this study illustrates the possibility of coordinating repeated assessments in real-world conditions, with families recruited and followed throughout the protocol, while precisely documenting what the results reveal.
Source and transparency. Gille I. et al., “Evaluation of Acute and Sustained Cognitive Effects of a Grape and Blueberry Polyphenol-Rich Extract in Healthy 7-12 Year Old Children: A Home-Based, Real-World Consumer Study,” Journal of Nutrition & Health , March 14, 2026. Read the publication . The study was funded by Activ'Inside, which provided the product studied; the authors of the scientific article are employees of Activ'Inside. The publication thanks the SYRES team for clinical supervision and coordination.
